The patients with the highest quartile of GLP-1 showed the lowest rate of CAVD (31.3%, P < 0.001; Supplementary Table 2), and the highest quartile showed a significantly strong negative correlation with CAVD risk (OR = 0.115; 95% CI, 0.045–0.291), which demonstrated that a high dose of GLP-1 exerted an antagonistic effect on the odds risk of CAVD (Table 3). This evidence concerns the gene GCG and congenital bilateral aplasia of vas deferens from CFTR mutation.